dc.contributor.author
Anker, Stefan D.
dc.contributor.author
Butler, Javed
dc.contributor.author
Filippatos, Gerasimos
dc.contributor.author
Shahzeb Khan, Muhammad
dc.contributor.author
Ferreira, João Pedro
dc.contributor.author
Bocchi, Edimar
dc.contributor.author
Böhm, Michael
dc.contributor.author
Brunner‐La Rocca, Hans Pieter
dc.contributor.author
Choi, Dong‐Ju
dc.contributor.author
Chopra, Vijay
dc.contributor.author
Chuquiure, Eduardo
dc.contributor.author
Giannetti, Nadia
dc.contributor.author
Gomez‐Mesa, Juan Esteban
dc.contributor.author
Janssens, Stefan
dc.contributor.author
Januzzi, James L.
dc.contributor.author
Gonzalez‐Juanatey, Jose R.
dc.contributor.author
Merkely, Bela
dc.contributor.author
Nicholls, Stephen J.
dc.contributor.author
Perrone, Sergio V.
dc.contributor.author
Piña, Ileana L.
dc.contributor.author
Ponikowski, Piotr
dc.contributor.author
Senni, Michele
dc.contributor.author
Seronde, Marie‐France
dc.contributor.author
Sim, David
dc.contributor.author
Spinar, Jindrich
dc.contributor.author
Squire, Iain
dc.contributor.author
Taddei, Stefano
dc.contributor.author
Tsutsui, Hiroyuki
dc.contributor.author
Verma, Subodh
dc.contributor.author
Vinereanu, Dragos
dc.contributor.author
Zhang, Jian
dc.contributor.author
Jamal, Waheed
dc.contributor.author
Schnaidt, Sven
dc.contributor.author
Schnee, Janet M.
dc.contributor.author
Brueckmann, Martina
dc.contributor.author
Pocock, Stuart J.
dc.contributor.author
Zannad, Faiez
dc.contributor.author
Packer, Milton
dc.contributor.author
EMPEROR‐Preserved Trial Committees and Investigators
dc.date.accessioned
2022-02-01T11:52:10Z
dc.date.available
2022-02-01T11:52:10Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/33830
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33549
dc.description.abstract
Aims:
EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials.
Methods and results:
EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists.
Conclusion:
When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Heart failure with preserved ejection fraction
en
dc.subject
Sodium–glucose co-transporter 2 inhibitors
en
dc.subject
Empagliflozin
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1002/ejhf.2064
dcterms.bibliographicCitation.journaltitle
European Journal of Heart Failure
dcterms.bibliographicCitation.number
12
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
2383
dcterms.bibliographicCitation.pageend
2392
dcterms.bibliographicCitation.volume
22
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33251670
dcterms.isPartOf.issn
1388-9842
dcterms.isPartOf.eissn
1879-0844